20+ in-depth peptide profiles, GLP-1 comparisons, research protocols, reconstitution guides, and clinical trial data — all sourced from published research, all in one place.
Peptides went from a niche corner of research chemistry to a mainstream conversation in about three years. GLP-1s reshaped the obesity conversation. Athletes started naming recovery peptides on podcasts. Longevity clinics added IV drips to their menus. Here are the forces driving the interest — each one grounded in what is actually happening in clinical research, policy, and culture.
Semaglutide and tirzepatide produced weight-loss numbers that previous drugs could not match. Once Oprah, tech founders, and everyday patients started describing the experience publicly, the door opened for the rest of the peptide space. Retatrutide’s Phase 3 data (28.7% mean loss) keeps the story going.
Read the semaglutide profile →High-profile injury comebacks and podcast conversations pulled tissue-repair peptides out of the strength-sports underground. The preclinical data is genuinely interesting; the published human data is thinner than the hype suggests. We cover both sides.
Wolverine blend breakdown →Billion-dollar longevity labs, aging-biomarker startups, and Bryan Johnson-style protocols put mitochondrial peptides (MOTS-C, SS-31), telomere peptides (Epithalon), and NAD+ precursors in front of a much wider audience than 10 years ago.
Longevity protocols →As IBD, leaky-gut, and chronic-inflammation research expanded, peptides with gut-lining and NF-κB effects became a natural focal point. Researchers and clinicians looking beyond conventional protocols started reading the preclinical data closely.
BPC-157 profile →HHS Secretary Robert F. Kennedy Jr. has publicly framed the FDA’s role as “do the science and tell the public what they’ve learned.” That signal, plus renewed scrutiny of the FDA Category 2 list, has put compounded peptides back in the policy conversation.
FDA Category 2 explainer →Copper-peptide research has a decades-long track record in cosmetic science. The current wave of interest pulled that research out of dermatology journals and into the broader wellness conversation, with blend formulations now dominating search queries.
GHK-Cu profile →Whoop, Oura, and sleep-tracker culture made deep sleep a measurable goal. Peptides studied for slow-wave sleep or nighttime GH pulses (CJC-1295 / Ipamorelin, DSIP) moved into that conversation naturally.
Sleep protocols →Most peptide content online exists to sell something. Readers are actively searching for plain-English, citation-heavy explanations of what each peptide is, what studies exist, and what the FDA status actually says. That is the gap this site fills.
Start with Peptides 101 →Choose a research area to explore the peptides, protocols, and published data most relevant to your interests.
GLP-1 receptor agonists and peptides studied for metabolic effects and body composition changes.
Retatrutide • Tirzepatide • Semaglutide • Tesamorelin • MOTS-C • SLU-PP-332 →Peptides studied in preclinical models for wound healing, connective tissue, and injury recovery.
BPC-157 • TB-500 • WOLVERINE • GHK-Cu →Secretagogues that stimulate natural GH release through the pituitary axis.
CJC-1295 • Ipamorelin • Tesamorelin • MK-677 →Peptides studied for collagen synthesis, skin regeneration, and anti-aging applications.
GHK-Cu • GLOW Blend • KLOW Blend • BPC-157 →Peptides studied for immune modulation and inflammatory response regulation.
Thymosin Alpha-1 • KPV • Selank • BPC-157 →Peptides studied for cognitive enhancement, neuroprotective effects, and brain health.
Semax • Selank • Dihexa • SS-31 →Peptides studied for telomere biology, mitochondrial function, and age-related decline.
SS-31 • NAD+ • GHK-Cu • MOTS-C • Epithalon →Peptides studied for sleep architecture, nocturnal GH release, and optimizing recovery during sleep.
CJC-1295/Ipamorelin • Selank • Epithalon • BPC-157 →Side-by-side comparison of semaglutide, tirzepatide, and retatrutide with clinical trial data.
Includes weight loss data • Side effects • Approval timeline →The peptides people explore most on this site.
The most established GLP-1 therapy. 5 FDA-approved formulations including injectable and oral options.
First-in-class dual agonist. Beat semaglutide head-to-head in SURMOUNT-5.
The most discussed research peptide for tissue repair. Extensive preclinical data.
The most popular GH secretagogue stack. Synergistic 2-3x GH elevation.
28.7% weight loss in trials, the highest recorded. Potential 2027-28 approval.
The most recognized peptide recovery stack. Individual components have preclinical data.
Studied for skin, collagen, and anti-aging. Has some human topical data.
Studied for telomere biology and longevity. Russian clinical data available.
Everything you need for thorough peptide research, from preparation guides to clinical trial tracking.
Peptides are short chains of amino acids, the building blocks of proteins, that play essential roles throughout your body. They regulate everything from hormone signaling and immune function to tissue repair and metabolism. Your body naturally produces thousands of them.
In recent years, synthetic peptides have become one of the most exciting areas of biomedical research. Some, like semaglutide, have achieved FDA approval and are transforming how we approach conditions like obesity and diabetes. Others, like BPC-157 and Epithalon, show promising preclinical results and are actively being studied, though they haven't yet completed the clinical trial process needed for FDA approval.
This site gives you access to the actual published research behind every peptide we cover, mechanisms of action, clinical trial data, studied dosing ranges, side effect profiles, and FDA regulatory status. We believe informed decisions start with transparent, well-sourced information.
Every factual claim links to PubMed, ClinicalTrials.gov, or FDA documents.
When evidence is limited or only preclinical, we say so clearly. No spin.
We don't sell peptides, link to vendors, or accept advertising. Ever.